Imricor Medical Systems Inc
ASX:IMR

Watchlist Manager
Imricor Medical Systems Inc Logo
Imricor Medical Systems Inc
ASX:IMR
Watchlist
Price: 1.47 AUD Market Closed
Market Cap: 471.8m AUD

Intrinsic Value

The intrinsic value of one IMR stock under the Base Case scenario is 0.21 AUD. Compared to the current market price of 1.47 AUD, Imricor Medical Systems Inc is Overvalued by 86%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IMR Intrinsic Value
0.21 AUD
Overvaluation 86%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Imricor Medical Systems Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about IMR?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is IMR valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Imricor Medical Systems Inc.

Explain Valuation
Compare IMR to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about IMR?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Imricor Medical Systems Inc

Current Assets 52.4m
Cash & Short-Term Investments 50.3m
Receivables 254.7k
Other Current Assets 1.8m
Non-Current Assets 3.2m
PP&E 2.4m
Other Non-Current Assets 764.1k
Current Liabilities 2m
Accounts Payable 404.9k
Accrued Liabilities 1.5m
Other Current Liabilities 47.1k
Non-Current Liabilities 30.5m
Long-Term Debt 23.8m
Other Non-Current Liabilities 6.7m
Efficiency

Free Cash Flow Analysis
Imricor Medical Systems Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Imricor Medical Systems Inc

Revenue
748.6k USD
Cost of Revenue
-1.7m USD
Gross Profit
-998.8k USD
Operating Expenses
-18.3m USD
Operating Income
-19.3m USD
Other Expenses
-16.6m USD
Net Income
-36m USD
Fundamental Scores

IMR Profitability Score
Profitability Due Diligence

Imricor Medical Systems Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

Imricor Medical Systems Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

IMR Solvency Score
Solvency Due Diligence

Imricor Medical Systems Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
High Altman Z-Score
Negative Net Debt
Long-Term Solvency
55/100
Solvency
Score

Imricor Medical Systems Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMR Price Targets Summary
Imricor Medical Systems Inc

Wall Street analysts forecast IMR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMR is 2.18 AUD with a low forecast of 2.08 AUD and a high forecast of 2.33 AUD.

Lowest
Price Target
2.08 AUD
42% Upside
Average
Price Target
2.18 AUD
48% Upside
Highest
Price Target
2.33 AUD
59% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Imricor Medical Systems Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for IMR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one IMR stock?

The intrinsic value of one IMR stock under the Base Case scenario is 0.21 AUD.

Is IMR stock undervalued or overvalued?

Compared to the current market price of 1.47 AUD, Imricor Medical Systems Inc is Overvalued by 86%.

Back to Top